Project Details
Description
Recurrent Miscarriage (RM) is a multifactorial disease. The research programme focuses on the evaluation of diagnostic screening and therapy of couples with Recurrent Miscarriage. Research projects regarding RM will be performed within the Early Pregnancy Unit (EPU/AMC), in multicenter national setting (Dutch Fertility Consortium) or in an international setting (Promise network, UK; University of Chicago, USA, Miscarriage Clinic in Liverpool, UK, University of Brussels, and the Rigshospitalet, Copenhagen).
Recurrent miscarriage is associated with parental chromosome abnormalities, antiphospholipid antibody syndrome (APS), hereditary thrombophilia, thyroid auto immunity and uterus septum. All associated factors will be further investigated with regard to diagnostic strategies and/or potential therapeutic regimens. The applicant has already shown that parental chromosome testing does not reduce the number of handicapped children born and that anticoagulant therapy (NEJM 2010) and progesterone (NEJM 2015) is not of benefit in women with unexplained recurrent miscarriage.
For women with RM a randomised uterine septum transsection trial (TRUST study/ NTR1676) is ongoing within the Dutch Fertility Consortium, as are the T4life trial (NTR3364) on levothyroxine versus placebo in women with RM and thyroid autoimmunity, and the Alife 2 trial (NTR3361) on heparin versus expectant management in women with RM and hereditary thrombophilia.
Fertility Preservation The second researchline is the evaluation of safety and efficacy of fertility preservation options. The safety and efficacy of ovarian hyperstimulation regimens for purpose of fertility preservation in women with (breast) cancer is subject of the STIM trial (NTR4108). It is a collaborative effort with The Netherlands Cancer Institute /Antoni van Leeuwenhoek Hospital (NKI/AVL) and the Dutch Fertility Consortium. Clinical challenges of oocyte freezing like transgenerational oocyte freezing, and oocyte freezing in women with mosaic Turner syndrome will be studied. A follow up study on the health of children born after oocyte freezing in the Netherlands will be conducted.
Recurrent miscarriage is associated with parental chromosome abnormalities, antiphospholipid antibody syndrome (APS), hereditary thrombophilia, thyroid auto immunity and uterus septum. All associated factors will be further investigated with regard to diagnostic strategies and/or potential therapeutic regimens. The applicant has already shown that parental chromosome testing does not reduce the number of handicapped children born and that anticoagulant therapy (NEJM 2010) and progesterone (NEJM 2015) is not of benefit in women with unexplained recurrent miscarriage.
For women with RM a randomised uterine septum transsection trial (TRUST study/ NTR1676) is ongoing within the Dutch Fertility Consortium, as are the T4life trial (NTR3364) on levothyroxine versus placebo in women with RM and thyroid autoimmunity, and the Alife 2 trial (NTR3361) on heparin versus expectant management in women with RM and hereditary thrombophilia.
Fertility Preservation The second researchline is the evaluation of safety and efficacy of fertility preservation options. The safety and efficacy of ovarian hyperstimulation regimens for purpose of fertility preservation in women with (breast) cancer is subject of the STIM trial (NTR4108). It is a collaborative effort with The Netherlands Cancer Institute /Antoni van Leeuwenhoek Hospital (NKI/AVL) and the Dutch Fertility Consortium. Clinical challenges of oocyte freezing like transgenerational oocyte freezing, and oocyte freezing in women with mosaic Turner syndrome will be studied. A follow up study on the health of children born after oocyte freezing in the Netherlands will be conducted.
| Status | Active |
|---|---|
| Effective start/end date | 1/01/2012 → … |